Get notified of page updates

Categories Side Effects

FORCE's eXamining the Relevance of Articles for You (XRAY) program looks behind the headlines of cancer news to help you understand what the research means for you. XRAY is a reliable source of hereditary cancer research-related news and information.
How To Use XRAY ›
Showing 21 through 30 out of 40

Relevance: Medium-High

Most relevant for: People interested in using cannabis to relieve treatment side effects.

Study: Cannabis use among breast cancer patients

This study looked at patterns of cannabis use among breast cancer patients who are members of online health communities. Almost half of the study participants reported using cannabis to help manage treatment symptoms and side effects. The study also looked at reasons why patients used cannabis, where they obtained it and whether they perceived cannabis to be safe. While this study only looked at cannabis use among breast cancer patients it is likely results would be similar among patients diagnosed with other types of cancers. (posted 1/25/22)

Este artículo está disponible en español.

READ MORE  ›

Relevance: High

Most relevant for: People concerned about the impact of chemotherapy

Study: Physical activity may prevent chemotherapy-related cognitive decline in women with breast cancer

Many people experience chemo brain or chemo fog (cognitive effects) during and after chemotherapy. Researchers looked at the impact of physical activity on chemotherapy-related decline in memory, attention and information processing in women with breast cancer. This study shows that more physical activity before and during chemotherapy is linked to better information processing after chemotherapy. (Posted 1/6/22)

Este artículo está disponible en español.

READ MORE  ›

Relevance: Medium-High

Most relevant for: People with or considering breast implants

Update: Stronger guidance about breast implant safety

The FDA issued new guidance for breast implants so that all people with breast implants have the appropriate information to understand and make decisions about their healthcare. Required features include box warning, patient decision checklist, guidelines for screening for implant ruptures and patient device cards. (posted 12/14/21)

Este artículo está disponible en español.

READ MORE  ›

Relevance: Medium-High

Most relevant for: People with metastatic castration resistant prostate cancer

Study: Bone-protecting drugs cut the risks for fractures caused by metastatic prostate cancer treatments

Skeletal problems, especially bone fractures, are common in patients with advanced prostate cancer. To prevent these, many guidelines recommend the use of bone-protecting agents during treatment. The importance of giving a bone-protecting agent when treating patients with metastatic castration-resistant prostate cancer and bone metastases was confirmed in early results of an ongoing phase III trial. (11/5/21)

Este artículo está disponible en español.

READ MORE  ›

Relevance: Medium-High

Most relevant for: People with early-stage HER2-negative breast cancer and an inherited BRCA mutation

Guideline: ASCO guidelines recommend olaparib for people with early-stage, high-risk breast cancer and an inherited BRCA mutation

The American Society of Clinical Oncology (ASCO) has updated their breast cancer treatment guidelines to include treatment with the PARP inhibitor olaparib (Lynparza) for one year after completing chemotherapy, surgery and radiation (if used) to improve outcomes of people with an inherited mutation in BRCA1 or BRCA2 with early-stage, HER2-negative breast cancer who have a high risk for recurrence. (posted 8/6/21) Update: Based on results from the OlympiA Study, the FDA approved olaparib as adjuvant treatment for people with an inherited BRCA mutation who have been diagnosed with early-stage HER2-negative breast cancer and are at high risk for recurrence. (03/11/2022)

Este artículo está disponible en español.

READ MORE  ›

Relevance: High

Most relevant for: People considering screening mammography after getting a COVID-19 vaccine.

Guideline: Expert guidelines on COVID-19 vaccines and timing of breast screening tests

COVID-19 vaccines work by helping the immune system destroy the virus. Lymph nodes are an important part of the immune system. COVID-19 vaccines may cause temporary swelling in some lymph nodes, which may look suspicious on a mammogram.  The Society for Breast Imaging and other professional organizations have released recommendations for the timing of mammograms after COVID-19 vaccines.  (3/30/21)

Este artículo está disponible en español.

READ MORE  ›

Relevance: Medium-High

Most relevant for: Breast cancer patients taking or considering taking hormone therapy

Study: How breast cancer patients experience hormone therapy

Side effects from hormone therapy are a common reason that many men and women with hormone receptor-positive breast cancer stop treatment early. Some people never start hormone therapy. This study asked patients about their experiences with hormone (or endocrine) therapy. The results suggest that there may be ways to improve the number of patients who stick with therapy. Patients need better ways to manage hormone therapy-related side effects. (1/19/21)

Este artículo está disponible en español.

READ MORE  ›

Relevance: High

Most relevant for: People who receive chemotherapy for cancer treatment

Personal Story: Coping with chemotherapy-induced hair loss

Ovarian cancer survivor Stephanie Hess shared her personal story about how she coped with hair loss. This XRAY review also includes treatments to reduce this common side effect of chemotherapy. (9/28/20)

READ MORE  ›

Relevance: Medium-High

Most relevant for: People with metastatic triple-negative breast cancer

Guideline: FDA issues alert on a drug combination to treat triple-negative breast cancer

The immunotherapy drug Tecentriq (atezolizumab) is approved for use with Abraxane (nab-paclitaxel) to treat metastatic triple-negative breast cancer. Tecentriq is NOT approved for use with Taxol (paclitaxel). The Food and Drug Administration has issued an alert to doctors, researchers and patients warning that Tecentriq should not be used in combination with Taxol to treat patients with advanced triple-negative breast cancer. (09/18/20)

READ MORE  ›

Relevance: Medium-High

Most relevant for: People currently taking a CDK inhibitor

Guideline: FDA issues warning on CDK inhibitors

The U.S. Food and Drug Administration issued a safety alert for CDK inhibitors, including Ibrance (palbociclib), Kisqali (ribociclib), and Verzenio (abemaciclib). (9/24/19)

READ MORE  ›